Following advancement of the drug into development, Ionis Pharmaceuticals licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca. IONIS-AZ6-2.5-LRx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH). In conjunction with this milestone, AstraZeneca will pay a $30 million license fee to Ionis. AstraZeneca will be responsible for further development and commercialization of IONIS-AZ6-2.5-LRx. “This is…
Positive Top-Line Results Reported In Huntington’s Disease Treatment
IONIS-HTT Rx (RG6042) top-line data demonstrate significant reductions of disease-causing mutant huntingtin protein in people with Huntington’s disease. Ionis Pharmaceuticals, Inc. announced the presentation of positive top-line data from a completed Phase 1/2 study of IONIS-HTTRx (RG6042) in people with early stage Huntington’s disease (HD) at the 13th Annual CHDI HD conference. The data demonstrate that IONIS-HTTRx (RG6042) is the…
Ionis Licenses New Antisense Drug For Kidney Disease To AstraZeneca
Ionis Pharmaceuticals, Inc. has licensed IONIS-AZ5-2.5Rx (AZD2373) to AstraZeneca. IONIS-AZ5-2.5Rx is a Generation 2.5 antisense drug, discovered by Ionis and designed to inhibit an undisclosed target to treat a genetically associated form of kidney disease. AstraZeneca will be responsible for developing and commercializing IONIS-AZ5-2.5Rx. “This is the second drug to enter development under our strategic collaboration with AstraZeneca in…
